Enables the company to offer bulk delivery and smaller individually packed items
Quay’s new approved packing and distribution facility will enable the company to respond to client requirements for both bulk delivery of product and smaller individually packed items
UK-based pharmaceutical outsourcing specialist Quay Pharma is enhancing its support for clinical trials with the establishment of a dedicated packing and distribution facility at its Deeside headquarters.
The new £100,000 area, approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), will allow Quay to respond to client requirements for both bulk delivery of product and to meet increasing demands for just in time deliveries to support randomised and blinded studies.
Quay offers the filling of primary packs including bottles, tubes, blister packs, sachets and oral dosing syringes, followed by secondary packing. As well as providing multi language labelling, blinding and randomisation, working with its sister company, Chester Medical, a commercial packaging provider, Quay can provide individually designed patient packs to aid patient compliance and assist in trial success.
Quay also supports cold chain management, including shipping and storage to ensure product quality and security are maintained throughout the distribution process. The inclusion of tamper evident seals and code break labels can be incorporated as part of the packing process.
The new facility is the latest development for Quay’s purpose-designed £2.5m factory in Deeside, which was opened in June 2010 and offers a specialist services including formulation development, novel drug delivery design, analytical method development and clinical trial manufacture.
‘Quay has developed this service to assist a number of our clients for whom we have developed products, as they move through to Phase II and Phase III clinical trials,’ said Maireadh Pedersen, Chief Executive of Quay Pharma. ‘This is an important enhancement to our client offering, enabling us to continue to support our customers throughout their development phase.’